ArticleLancet regional health. Americas2026
Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin America: insights from a large multinational cohort.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Outcomes of adults with acute lymphoblastic leukemia (ALL) in Latin America remain poorly characterized, particularly across public and private healthcare systems. In this study, we evaluated overall survival (OS) and relapse rates in a multinational cohort, aiming to identify key factors associated with these outcomes. Methods: We retrospectively analyzed patients aged ≥15 years with newly diagnosed ALL treated at 45 centers in Brazil, Argentina, and Chile between 2015 and 2023. Overall survival (OS) and event-free survival (EFS) were estimated using Kaplan-Meier methods. Cox models incorporating country as a shared frailty term evaluated factors associated with mortality. Findings: Among 1121 patients, median age was 34 years, 56.1% were male, 81.4% had B-lineage ALL, and 24.7% had Philadelphia chromosome-positive (Ph-positive) ALL. Overall, 53% were treated in public centers. Induction mortality was higher in public than private settings (10.0% vs. 1.2%; p < 0.0001), whereas hematopoietic stem cell transplantation was less frequent (18.1% vs. 46.6%; p < 0.0001). At a median follow-up of 36.2 months, 3-year OS and EFS were 49.9% and 41.1%, respectively. Three-year OS was 42.9% in public and 57.6% in private centers (p < 0.0001). Private healthcare remained independently associated with lower mortality overall (HR 0.53, 95% CI 0.42-0.68) and across major subgroups. Three-year relapse incidence was 43.9%. Among Ph-negative adolescents and young adults, male sex and leukocytosis were independently associated with increased mortality. In Ph-positive ALL, upfront dasatinib was associated with improved OS, primarily through lower non-relapse mortality rather than reduced relapse incidence. Interpretation: Survival of adults with ALL in Latin America has improved compared with historical reports, but substantial disparities persist between public and private settings. Our findings support prioritizing investment in public-sector supportive care, diagnostic and treatment infrastructure, timely access to transplantation, and equitable availability of effective therapies as key strategies to improve survival across the region. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.